A phase I, pharmacokinetic and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors

PURPOSE: Panobinostat, a histone deacetylase (HDAC) inhibitor, enhances anti-proliferative activity in non-small cell lung cancer (NSCLC) cell lines when combined with erlotinib. We evaluated this combination in advanced NSCLC and head-and-neck (H&N) cancer patients. EXPERIMENTAL DESIGN: Eligibl...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gray, Jhanelle E., Haura, Eric, Chiappori, Alberto, Tanvetyanon, Tawee, Williams, Charles C., Pinder-Schenck, Mary, Kish, Julie A., Kreahling, Jenny, Lush, Richard, Neuger, Anthony, Tetteh, Leticia, Akar, Angela, Zhao, Xiuhua, Schell, Michael J., Bepler, Gerold, Altiok, Soner
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4051132/
https://ncbi.nlm.nih.gov/pubmed/24429877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-2235
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares